<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2019.10980</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-10980</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Shikonin regulates invasion and autophagy of cultured colon cancer cells by inhibiting yes-associated protein</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Jing</given-names></name>
<xref rid="af1-ol-0-0-10980" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-10980" ref-type="aff">2</xref>
<xref rid="fn1-ol-0-0-10980" ref-type="author-notes">&#x002A;</xref>
<xref rid="c1-ol-0-0-10980" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Lei</given-names></name>
<xref rid="af3-ol-0-0-10980" ref-type="aff">3</xref>
<xref rid="fn1-ol-0-0-10980" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Luo</surname><given-names>Bin</given-names></name>
<xref rid="af2-ol-0-0-10980" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Wang</given-names></name>
<xref rid="af1-ol-0-0-10980" ref-type="aff">1</xref>
<xref rid="c1-ol-0-0-10980" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-10980"><label>1</label>Laboratory of Cancer, College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, P.R. China</aff>
<aff id="af2-ol-0-0-10980"><label>2</label>Department of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China</aff>
<aff id="af3-ol-0-0-10980"><label>3</label>Reproductive Medicine Centre, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-10980"><italic>Correspondence to</italic>: Dr Wang Sheng or Dr Jing Zhu, Laboratory of Cancer, College of Life Science and Bioengineering, Beijing University of Technology, 100 Pingleyuan, Chaoyang, Beijing 100124, P.R. China, E-mail: <email>shengwang@bjut.edu.en</email>, E-mail: <email>jing_Zhu0719@163.com</email></corresp>
<fn id="fn1-ol-0-0-10980"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>12</month>
<year>2019</year></pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2019</year></pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>6117</fpage>
<lpage>6125</lpage>
<history>
<date date-type="received"><day>25</day><month>02</month><year>2019</year></date>
<date date-type="accepted"><day>06</day><month>09</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhu et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Colon cancer is a common malignancy, and its morbidity and mortality have been increasing in recent years in China. Shikonin (Shi), a naturally occurring naphthoquinone, exhibits anticancer activity. However, the mechanisms of action of Shi remain unclear. The aim of the present study was to investigate the antitumor mechanism of Shi in colon cancer cells. The effects of different Shi concentrations on the viability of colon cancer cells using MTT, colony formation and wound-healing assays were assessed. Western blot analysis was performed to detect the expression of LC3-II, p62. Shi effectively suppressed viability and cell migration, and induced autophagy in colon cancer cells. Yes-associated protein (YAP) increases cell viability, and inhibits cell apoptosis and cell contact. Expression of YAP is downregulated by Shi. The cytotoxic effects of Shi were further investigated on YAP overexpression and on YAP knockout cell lines. The findings revealed that Shi suppressed the viability and induced autophagy of colon cancer cells. Additionally, YAP expression reversed the effects of Shi. The results of the present study suggest that Shi may be a promising anticancer treatment for colon cancer, and YAP may be a potential diagnostic marker for colon cancer.</p>
</abstract>
<kwd-group>
<kwd>colon cancer</kwd>
<kwd>shikonin</kwd>
<kwd>autophagy</kwd>
<kwd>yes-associated protein</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Cancer is the second largest cause of death in the world (<xref rid="b1-ol-0-0-10980" ref-type="bibr">1</xref>). Colon cancer is the fourth leading cause of all cancer-associated deaths worldwide. With increases in population size and age, the incidence rate of colorectal cancer is increasing year by year in China (<xref rid="b2-ol-0-0-10980" ref-type="bibr">2</xref>). In 2014, an estimated 71,830 men and 65,000 women were diagnosed with colorectal cancer and 26,270 men and 24,040 women died of the disease (<xref rid="b3-ol-0-0-10980" ref-type="bibr">3</xref>). At present, the treatments for colon cancer include surgical resection, radiation therapy and adjuvant chemotherapy. Radiotherapy and chemotherapy have well-established side effects in patients with colon cancer (<xref rid="b4-ol-0-0-10980" ref-type="bibr">4</xref>). Therefore, searching for effective drugs with fewer side effects remains a major task for researchers.</p>
<p>Hippo signaling pathways are important for maintaining organ size and tumor development (<xref rid="b5-ol-0-0-10980" ref-type="bibr">5</xref>). Yes-associated protein (YAP) is a cancer-associated oncogene and is one of the Hippo signaling pathway downstream signaling molecules (<xref rid="b6-ol-0-0-10980" ref-type="bibr">6</xref>). YAP can induce cell proliferation, restrain cell apoptosis, reduce cell contact inhibition and accelerate cancer cell transformation. Wang and Tang (<xref rid="b7-ol-0-0-10980" ref-type="bibr">7</xref>) reported that the protein expression levels of YAP in liver cancer were upregulated. Shikonin (Shi), which is extracted from <italic>Lithospermum erythrorhizon</italic>, has been used to treat burns, sore throats, measles and other ailments in China since 1963 (<xref rid="b8-ol-0-0-10980" ref-type="bibr">8</xref>). Recent research has shown that Shi has antitumor potential in various types of cancer cell lines, including pancreatic cancer, non-small cell lung cancer (<xref rid="b9-ol-0-0-10980" ref-type="bibr">9</xref>,<xref rid="b10-ol-0-0-10980" ref-type="bibr">10</xref>).</p>
<p>The aim of the present study was to assess the proliferation, cell migration and autophagy <italic>in vitro</italic> to investigate the effects of Shi on human colon HCT116 and SW620 cells, and to assess whether YAP was a target of Shi in these cell lines. The results showed that Shi inhibited proliferation, induced autophagy and inhibited migration of human colon cells. Additionally, Shi reduced the expression of YAP, whereas YAP overexpression reversed the effects of Shi on colon cancer. The results suggest that Shi may potentially be used as a treatment due to its ability to reduce YAP expression and reverse autophagy of colon cancer cells.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Reagents</title>
<p>Shi was purchased from the Shanghai Technology Institute of Yuanye. The chemical structure of Shi is shown in <xref rid="f1-ol-0-0-10980" ref-type="fig">Fig. 1</xref>.</p>
</sec>
<sec>
<title>Cell culture</title>
<p>The colon cancer cell lines, HCT116 and SW620, were purchased from the American Type Culture Collection. HCT116 and SW620 cells were cultured in McCoy&#x0027;s 5A and L-15 medium, respectively, containing 10&#x0025; FBS (HyClone; GE Healthcare Life Sciences), 100 U/ml penicillin and 100 mg/ml streptomycin (both Amresco; VWR International, LLC). All cells were cultured at 37&#x00B0;C in a humidified atmosphere with 5&#x0025; CO<sub>2</sub>.</p>
</sec>
<sec>
<title>MTT assay</title>
<p>Both HCT116 and SW620 cells (8&#x00D7;10<sup>3</sup> cells/well) were seeded in 96-well plates. Shi (0, 1, 2.5, 5, 7.5 and 10 &#x00B5;M) was added to the cells at the different concentrations stated and incubated for 24 and 48 h. Subsequently, MTT solution (10 mg/ml) was added. Cells were cultured for a further 2 h at 37&#x00B0;C, and 100 &#x00B5;l DMSO was added. The optical density of each well was measured at 570 nm and the inhibition rate was calculated using the following equation: Inhibition rate (&#x0025;)=(average A570 of the control group-average A570 of the experimental group)/(average A570 of the control group-average A570 of the blank group) &#x00D7;100. All MTT assays were repeated at least three times. The control group was the cells treated with DMSO alone, and the blank group was the wells without cells added.</p>
</sec>
<sec>
<title>Colony formation assay</title>
<p>HCT116 and SW620 cells were cultured in a 6-well plate at a density of 1&#x00D7;10<sup>3</sup> cells/well, and treated with Shi (0, 5 or 10 &#x00B5;M). After three weeks, cells were stained with crystal violet staining solution for 30 min at room temperature (Beyotime Institute of Biotechnology) and the visible colonies were counted under an optical light microscope at &#x00D7;4 magnification (IX70; Olympus Corporation).</p>
</sec>
<sec>
<title>Wound-healing assay</title>
<p>HCT116 cells were cultured in McCoy&#x0027;s 5A medium and SW620 cells were cultured in L-15 without FBS. The cells were cultured in 6-well plates and grown to 100&#x0025; confluence. A 200 &#x00B5;l pipette was used to create the wound, then PBS was used to wash the cell debris, and serum-free medium was added. Cells were treated with 10 &#x00B5;M Shi, and wound closure was observed using an inverted light microscope at a &#x00D7;4 magnification imaged using a digital camera. The extent of wound healing is defined as the ratio of the difference of wound area. All the experiments were repeated three times.</p>
</sec>
<sec>
<title>Transfection</title>
<p>The HCT116 and SW620 cells (3&#x00D7;10<sup>5</sup> cells/well) were grown in 6-well plates, treated with various concentrations of Shi and transfected with YAP cDNA or YAP small interfering (si)RNA or empty vector using lipofectamine<sup>&#x00AE;</sup> 3000 according to the manufacturer&#x0027;s protocol. YAP siRNA oligonucleotides were purchased from GenePharma (Shanghai, China) and the sequences were; forward, 5&#x2032;-GGUGAUACUAUCAACCAAATT-3&#x2032;; and reverse, 5&#x2032;-UUUGGUUGAUAGUAUCACCTT-3&#x2032;. After 48 h of transfection with the lentiviral vectors (Biofeng, Guangzhou, China), successfully transfected cell lines were selected for using puromycin (Santa Cruz Biotechnology, Inc.) for 21 days.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Cells were harvested using RIPA lysis buffer (Beyotime Institute of Biotechnology) and protein concentration was determined using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology). Soluble proteins were extracted from the cell lysate using 150 mM NaCl, 50 mM Tris, pH 8.0, 30&#x0025; Acrylamide-Bis-acrylamide, 10&#x0025; SDS, 1 mM PMSF, 1 mM sodium vanadate (Beyotime, Shanghai, China). A total of 25 &#x00B5;g protein were loaded into 10 or 15&#x0025; SDS gels and resolved using SDS-PAGE. Subsequently, resolved proteins were transferred to PVDF membranes (EMD Millipore) and blocked in 5&#x0025; skimmed milk for 2 h at 37&#x00B0;C. The membranes were incubated with primary antibodies at 4&#x00B0;C overnight and then washed with TBS-Tween-20. The primary antibodies used were: Anti-GAPDH (1:1,000; cat. no. AF0006; Beyotime Institute of Biotechnology); anti-LC3 (1:1,000; cat. no. 3868T; CST Biological Reagents Co., Ltd.); anti-P62 (1:1,000; cat. no. no. 5114T; CST Biological Reagents Co., Ltd.); anti-YAP (1:1,000; cat. no. 14074; CST Biological Reagents Co., Ltd.), anti-phospho-(p-)YAP (S127) (1:1,000; cat. no. 4911; CST Biological Reagents Co., Ltd.). Subsequently, membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (1:5,000; cat. nos. E030120-01 and E030110-01; EarthOx Life Sciences) at room temperature for 1 h. Signals were visualized using a SuperSignal<sup>&#x00AE;</sup> West Pico Trial kit (Pierce; Thermo Fisher Scientific, Inc.). ImageJ 1.43U (National Institutes of Health) was used for densitometry analysis.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>In the present study, all experiments were repeated at least three times and the results were analyzed using GraphPad Prism v5.0 (GraphPad Software, Inc.) and SPSS v17.0 (SPSS, Inc.). Data are presented as the mean &#x00B1; standard deviation. Results were analyzed using an unpaired Student&#x0027;s t-test or one-way ANOVA followed by a Bonferroni&#x0027;s post-hoc test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Shi decreases the viability and suppresses migration of HCT116 and SW620 cells</title>
<p>Shi is a natural plant extract which exhibits antiproliferative effects on cancer cell growth (<xref rid="b8-ol-0-0-10980" ref-type="bibr">8</xref>). The chemical structure of Shi is shown in <xref rid="f1-ol-0-0-10980" ref-type="fig">Fig. 1</xref>. The effect of Shi on HCT116 and SW620 cells was investigated using an MTT assay, and the results showed that as Shi concentration or treatment time was increased, cell viability of HCT116 and SW620 cells appeared to be reduced (<xref rid="f2-ol-0-0-10980" ref-type="fig">Fig. 2A and B</xref>). Colony formation assays showed a significant decrease in colony formation following Shi treatment and this appeared to be dose-dependent (<xref rid="f2-ol-0-0-10980" ref-type="fig">Fig. 2C and D</xref>). Subsequently wound-healing assays were performed to examine the effects of Shi on colon cancer cells migration. When the cell density reached 100&#x0025;, wounds were created with a pipette tip, and 10 &#x00B5;M Shi was added. After 24 h, wound closure in the HCT116 and SW620 cells was ~35 and 55&#x0025;, respectively. Shi treatment significantly slowed wound closure in HCT116 (50&#x0025;) and SW620 (80&#x0025;) cells compared with the respective control (<xref rid="f2-ol-0-0-10980" ref-type="fig">Fig. 2E and F</xref>). All these results showed that Shi exhibited cytotoxic effects on HCT116 and SW620 cells.</p>
</sec>
<sec>
<title>Shi induces autophagy and reduces YAP expression in HCT116 and SW620 cells</title>
<p>Increasing evidence suggests that autophagy is an important mechanism of death in cancer cells and may be of importance in the development of tumors (<xref rid="b11-ol-0-0-10980" ref-type="bibr">11</xref>). To evaluate whether autophagy was involved in Shi-induced cell death, the expression levels of LC3-II and p62 were evaluated in Shi-treated cells. HCT116 and SW620 cells were treated with 0, 2.5, 5 or 10 &#x00B5;M Shi for 24 h, or with 10 &#x00B5;M Shi for 0, 6, 12 or 24 h. After autophagy begins, the C-terminal LC3 is cleaved to produce the LC3II protein, which then translocates to autophagosomes (<xref rid="b12-ol-0-0-10980" ref-type="bibr">12</xref>). The expression of LC3-II was detected using western blot analysis and the results suggested that increasing Shi concentrations resulted in significantly upregulated LC3-II expression (<xref rid="f3-ol-0-0-10980" ref-type="fig">Fig. 3A-D</xref>). The degradation of p62 (also known as sequestosome 1) is considered an accurate indicator of autophagy. Therefore, the expression of p62 in colon cancer cells treated with Shi was investigated. As the concentration of Shi used or the treatment time was increased, degradation of P62 became more notable in HCT116 and SW620 cells and the difference was significant compared with the control group (P&#x003C;0.05) (<xref rid="f3-ol-0-0-10980" ref-type="fig">Fig. 3A-D</xref>). In conclusion, these findings suggest that Shi induced autophagy in colon cancer cells. In addition, the changes in expression of YAP was also studied. The expression of YAP in HCT116 and SW620 cells treated with Shi was downregulated as the concentration or treatment with Shi was increased, and the difference was significant compared with the control group (P&#x003C;0.05; <xref rid="f3-ol-0-0-10980" ref-type="fig">Fig. 3E-H</xref>). Meanwhile, the serine<sup>127</sup> phosphorylation of YAP in HCT116 and SW620 cells was also detected (<xref rid="f3-ol-0-0-10980" ref-type="fig">Fig. 3E-H</xref>), suggesting that Shi could upregulate YAP phosphorylation. All these data concluded that Shi decreased the protein expression of YAP.</p>
</sec>
<sec>
<title>Overexpression of YAP antagonizes the inhibitory effect of Shi in HCT116 and SW620 cells</title>
<p>To detect whether YAP serves a critical role in the inhibitory effect of Shi on colon cancer, HCT116 and SW620 cells were transfected with the YAP-specific cDNA and subsequently treated with 10 &#x00B5;M Shi for 24 h (<xref rid="f4-ol-0-0-10980" ref-type="fig">Fig. 4A and B</xref>). The results showed that overexpression of YAP promoted colon cancer cell growth and reversed the inhibition of Shi on cell growth to a certain extent. In addition, as shown in the <xref rid="f4-ol-0-0-10980" ref-type="fig">Fig. 4C and D</xref>, YAP overexpression decreased the percentage of autophagy in HCT116 cells and SW620 cells. Additionally, LC3II protein expression levels were increased and p62 levels were decreased (<xref rid="f4-ol-0-0-10980" ref-type="fig">Fig. 4C and D</xref>) in both cell lines. Densitometry analysis of LC3-II, P62 and YAP expression levels are shown in <xref rid="f4-ol-0-0-10980" ref-type="fig">Fig. 4E-H</xref>. These results showed that the anticancer activity of Shi is partly caused by the inactivation of YAP.</p>
</sec>
<sec>
<title>Knockdown of YAP increases sensitivity of colon cancer cells to Shi</title>
<p>To investigate whether the cytotoxicity of Shi is related to the regulation of YAP, viability assays were performed in HCT116 and SW620 cells. The HCT116 and SW620 cells were transfected with YAP-specific siRNA. The results show that downregulation of YAP decreased cell viability compared with the control group and caused colon cancer cells to become more sensitive to Shi. Shi and YAP siRNA only compared with control group and YAP siRNA &#x002B; Shi group compared with YAP siRNA group (<xref rid="f5-ol-0-0-10980" ref-type="fig">Fig. 5A and B</xref>). Moreover, it was found that the expression of LC3-II increased and expression of p62 decreased in the Shi and YAP siRNA only group compared with the control group, and in the YAP siRNA &#x002B; Shi group compared with YAP siRNA group (<xref rid="f5-ol-0-0-10980" ref-type="fig">Fig. 5C and D</xref>). Therefore Shi and YAP siRNA showed stronger induction of autophagy compared with siRNA transfection or Shi alone. Densitometry analysis of LC3-II, p62 and YAP expression levels are presented in <xref rid="f5-ol-0-0-10980" ref-type="fig">Fig. 5E-H</xref>. The results showed that the synergistic effects of YAP-specific siRNA and Shi increased Shi-induced autophagy in colon cancer cells.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>A number of novel anticancer drugs are extracted from plants (<xref rid="b13-ol-0-0-10980" ref-type="bibr">13</xref>), and drugs obtained from plants have shown potential antitumor effects. Shi, which is a type of naphthoquinone extracted from the herbal plant <italic>Lithospermum erythrorhizon</italic>, and is considered to have anti-inflammatory and antivirus effects (<xref rid="b14-ol-0-0-10980" ref-type="bibr">14</xref>). In a previous colon cancer study, it was reported that Shi increased apoptosis in cisplatin-induced cancer cells (<xref rid="b15-ol-0-0-10980" ref-type="bibr">15</xref>). The effectiveness and safety of Shi for colon cancer requires further investigation. In the present study, Shi suppressed the viability and migration, and induced autophagy of the human HCT116 and SW620 colon cancer cell lines. The growth and migration of HCT116 and SW620 cells was significantly inhibited by Shi based on the results of the MTT, colony formation and wound-healing assays. Meanwhile, cell autophagy appeared to be increased by Shi in a dose- and time-dependent manner. These results strongly indicate that Shi has chemotherapeutic potential to treat patients with colon cancer.</p>
<p>Autophagy is a highly conserved cellular process and a biologically programmed form of cell death (<xref rid="b16-ol-0-0-10980" ref-type="bibr">16</xref>). Shi and Cao (<xref rid="b9-ol-0-0-10980" ref-type="bibr">9</xref>) reported that Shi could induce autophagy in the pancreatic BXPC3 cell line. In autophagy, LC3-II serves a role in the formation of autophagosomes and p62 is an autophagy marker (<xref rid="b17-ol-0-0-10980" ref-type="bibr">17</xref>). In the present study, the protein expression levels of LC3-II and p62 were altered resulting in activation of autophagy in cells treated with Shi. It has been demonstrated that Shi could induce autophagy in HCT116 and SW620 cells.</p>
<p>In 1995, the Hippo signaling pathway was first described (<xref rid="b18-ol-0-0-10980" ref-type="bibr">18</xref>). YAP is an effector of the Hippo-YAP signaling pathway in mammals, and can reduce excessive proliferation of cancer cells (<xref rid="b19-ol-0-0-10980" ref-type="bibr">19</xref>). Reduced expression of YAP is associated with autophagy and differentiation in carcinoma cells (<xref rid="b20-ol-0-0-10980" ref-type="bibr">20</xref>). Activation of YAP is involved in the development in cancer of the liver and the lung cancer amongst others (<xref rid="b21-ol-0-0-10980" ref-type="bibr">21</xref>). Therefore YAP has become a novel marker for cancer treatment (<xref rid="b22-ol-0-0-10980" ref-type="bibr">22</xref>,<xref rid="b23-ol-0-0-10980" ref-type="bibr">23</xref>). Phosphorylated YAP is sequestered in the cytoplasm by binding to 14-3-3 proteins thus; YAP cannot enter the nucleus, resulting in inhibition of its activity (<xref rid="b24-ol-0-0-10980" ref-type="bibr">24</xref>). In the present study, the expression of YAP was significantly reduced, and YAP phosphorylation was upregulated in colon cancer cells treated with Shi. Autophagy of colon cancer cells was related to the change in expression of YAP, suggesting that autophagy and YAP may be associated with the cytotoxic effects of Shi on colon cancer cells.</p>
<p>In conclusion, Shi is an effective suppressor of cell survival and invasion as well as an inducer of autophagy in colon cancer cells. In addition, Shi was found to reduce the expression of YAP and reverse the effects of YAP on colon cancer cells. Therefore YAP may be used as a potential diagnostic marker of colon cancer.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>This study was supported by the National Natural Technology Foundation of China (Beijing, China; grant no. 81428016) and the Key Program for Science and Technology Development of Beijing (Beijing, China; grant no. Z151100003915073).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>JZ drafted the manuscript. JZ and LZ performed experiments and data analysis. WS and BL performed the statistical analysis. All the authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-10980"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouffret</surname><given-names>L</given-names></name><name><surname>Turrini</surname><given-names>O</given-names></name><name><surname>Ewald</surname><given-names>J</given-names></name><name><surname>Moutardier</surname><given-names>V</given-names></name><name><surname>Iovanna</surname><given-names>JL</given-names></name><name><surname>Delpero</surname><given-names>JR</given-names></name></person-group><article-title>Long-term survivors after pancreatectomy for cancer: The TNM classification is outdated</article-title><source>ANZ J Surg</source><volume>85</volume><fpage>860</fpage><lpage>864</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/ans.13277</pub-id><pub-id pub-id-type="pmid">26331377</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-10980"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><volume>65</volume><fpage>87</fpage><lpage>108</lpage><year>2015</year><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-10980"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname><given-names>CE</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Mariotto</surname><given-names>AB</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Stein</surname><given-names>KD</given-names></name><name><surname>Kramer</surname><given-names>JL</given-names></name><name><surname>Alteri</surname><given-names>R</given-names></name><name><surname>Robbins</surname><given-names>AS</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer treatment and survivorship statistics, 2014</article-title><source>CA Cancer J Clin</source><volume>64</volume><fpage>252</fpage><lpage>271</lpage><year>2014</year><pub-id pub-id-type="doi">10.3322/caac.21235</pub-id><pub-id pub-id-type="pmid">24890451</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-10980"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>KE</given-names></name><name><surname>Taylor</surname><given-names>TH</given-names></name><name><surname>Pan</surname><given-names>CG</given-names></name><name><surname>Stamos</surname><given-names>MJ</given-names></name><name><surname>Zell</surname><given-names>JA</given-names></name></person-group><article-title>Colorectal cancer incidence among young adults in California</article-title><source>J Adolesc Young Adult Oncol</source><volume>3</volume><fpage>176</fpage><lpage>184</lpage><year>2014</year><pub-id pub-id-type="doi">10.1089/jayao.2014.0006</pub-id><pub-id pub-id-type="pmid">25538862</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-10980"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SP</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><article-title>Disease implication of hyper-Hippo signalling</article-title><source>Open Biol</source><volume>6</volume><year>2016</year><pub-id pub-id-type="doi">10.1098/rsob.160119</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-10980"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>HX</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ</article-title><source>Cancer Res</source><volume>77</volume><fpage>2413</fpage><lpage>2423</lpage><year>2017</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3229</pub-id><pub-id pub-id-type="pmid">28249901</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-10980"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YP</given-names></name><name><surname>Tang</surname><given-names>DX</given-names></name></person-group><article-title>Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients</article-title><source>Int J Clin Exp Med</source><volume>8</volume><fpage>1080</fpage><lpage>1086</lpage><year>2015</year><pub-id pub-id-type="pmid">25785096</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-10980"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>Anticancer agent shikonin is an incompetent inducer of cancer drug resistance</article-title><source>PLoS One</source><volume>8</volume><fpage>e52706</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0052706</pub-id><pub-id pub-id-type="pmid">23300986</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-10980"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name></person-group><article-title>Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway</article-title><source>Oncol Lett</source><volume>8</volume><fpage>1087</fpage><lpage>1089</lpage><year>2014</year><pub-id pub-id-type="doi">10.3892/ol.2014.2293</pub-id><pub-id pub-id-type="pmid">25120662</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-10980"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Hwang</surname><given-names>KE</given-names></name><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Jun</surname><given-names>HY</given-names></name><name><surname>Yoon</surname><given-names>KH</given-names></name><name><surname>Jeong</surname><given-names>ET</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells</article-title><source>J Transl Med</source><volume>15</volume><fpage>123</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12967-017-1223-7</pub-id><pub-id pub-id-type="pmid">28569199</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-10980"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>HR</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Functional role of autophagy in gastric cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>17641</fpage><lpage>17651</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.7508</pub-id><pub-id pub-id-type="pmid">26910278</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-10980"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname><given-names>DJ</given-names></name><name><surname>Abeliovich</surname><given-names>H</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Agrawal</surname><given-names>DK</given-names></name><name><surname>Aliev</surname><given-names>G</given-names></name><name><surname>Askew</surname><given-names>DS</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Baehrecke</surname><given-names>EH</given-names></name><name><surname>Bahr</surname><given-names>BA</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes</article-title><source>Autophagy</source><volume>4</volume><fpage>151</fpage><lpage>175</lpage><year>2008</year><pub-id pub-id-type="doi">10.4161/auto.5338</pub-id><pub-id pub-id-type="pmid">18188003</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-10980"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlender</surname><given-names>M</given-names></name><name><surname>Kapulnik</surname><given-names>Y</given-names></name><name><surname>Koltai</surname><given-names>H</given-names></name></person-group><article-title>Plant derived substances with anti-cancer activity: From folklore to practice</article-title><source>Front Plant Sci</source><volume>6</volume><fpage>799</fpage><year>2015</year><pub-id pub-id-type="doi">10.3389/fpls.2015.00799</pub-id><pub-id pub-id-type="pmid">26483815</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-10980"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Jiang Hda</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>SS</given-names></name></person-group><article-title>Comparative study on enantiomeric excess of main akannin/shikonin derivatives isolated from the roots of three endemic Boraginaceae plants in China</article-title><source>Biomed Chromatogr</source><volume>25</volume><fpage>1067</fpage><lpage>1075</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/bmc.1570</pub-id><pub-id pub-id-type="pmid">21308700</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-10980"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Pi</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><article-title>Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo</article-title><source>Biochem Biophys Res Commun</source><volume>469</volume><fpage>1075</fpage><lpage>1082</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.12.100</pub-id><pub-id pub-id-type="pmid">26740178</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-10980"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petherick</surname><given-names>KJ</given-names></name><name><surname>Williams</surname><given-names>AC</given-names></name><name><surname>Lane</surname><given-names>JD</given-names></name><name><surname>Ord&#x00F3;&#x00F1;ez-Mor&#x00E1;n</surname><given-names>P</given-names></name><name><surname>Huelsken</surname><given-names>J</given-names></name><name><surname>Collard</surname><given-names>TJ</given-names></name><name><surname>Smartt</surname><given-names>HJ</given-names></name><name><surname>Batson</surname><given-names>J</given-names></name><name><surname>Malik</surname><given-names>K</given-names></name><name><surname>Paraskeva</surname><given-names>C</given-names></name><name><surname>Greenhough</surname><given-names>A</given-names></name></person-group><article-title>Autolysosomal &#x03B2;-catenin degradation regulates Wnt-autophagy-p62 crosstalk</article-title><source>EMBO J</source><volume>32</volume><fpage>1903</fpage><lpage>1916</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/emboj.2013.123</pub-id><pub-id pub-id-type="pmid">23736261</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-10980"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Lei</surname><given-names>YH</given-names></name><name><surname>Yao</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>CR</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Ye</surname><given-names>WC</given-names></name><name><surname>Zhang</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>ZS</given-names></name></person-group><article-title>Autophagy and multidrug resistance in cancer</article-title><source>Chin J Cancer</source><volume>36</volume><fpage>52</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s40880-017-0219-2</pub-id><pub-id pub-id-type="pmid">28646911</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-10980"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>RA</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name></person-group><article-title>Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene encodes a putative protein kinase</article-title><source>Development</source><volume>121</volume><fpage>1053</fpage><lpage>1063</lpage><year>1995</year><pub-id pub-id-type="pmid">7743921</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-10980"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name></person-group><article-title>Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer</article-title><source>Eur J Cancer</source><volume>48</volume><fpage>1227</fpage><lpage>1234</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ejca.2011.10.001</pub-id><pub-id pub-id-type="pmid">22056638</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-10980"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name></person-group><article-title>A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells</article-title><source>Am J Transl Res</source><volume>9</volume><fpage>3212</fpage><lpage>3223</lpage><year>2017</year><pub-id pub-id-type="pmid">28804541</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-10980"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroishi</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>CG</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>The emerging roles of YAP and TAZ in cancer</article-title><source>Nat Rev Cancer</source><volume>15</volume><fpage>73</fpage><lpage>79</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/nrc3876</pub-id><pub-id pub-id-type="pmid">25592648</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-10980"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>The Hippo signaling pathway in stem cell biology and cancer</article-title><source>EMBO Rep</source><volume>15</volume><fpage>642</fpage><lpage>656</lpage><year>2014</year><pub-id pub-id-type="doi">10.15252/embr.201438638</pub-id><pub-id pub-id-type="pmid">24825474</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-10980"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>LS</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name></person-group><article-title>Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells</article-title><source>Int J Mol Sci</source><volume>15</volume><fpage>15173</fpage><lpage>15187</lpage><year>2014</year><pub-id pub-id-type="doi">10.3390/ijms150915173</pub-id><pub-id pub-id-type="pmid">25170806</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-10980"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oku</surname><given-names>Y</given-names></name><name><surname>Nishiya</surname><given-names>N</given-names></name><name><surname>Shito</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>C</given-names></name><name><surname>Uehara</surname><given-names>Y</given-names></name></person-group><article-title>Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers</article-title><source>FEBS Open Bio</source><volume>5</volume><fpage>542</fpage><lpage>549</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.fob.2015.06.007</pub-id><pub-id pub-id-type="pmid">26199863</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-10980" position="float">
<label>Figure 1.</label>
<caption><p>Chemical structure of shikonin.</p></caption>
<graphic xlink:href="ol-18-06-6117-g00.tif"/>
</fig>
<fig id="f2-ol-0-0-10980" position="float">
<label>Figure 2.</label>
<caption><p>Shi inhibits cell growth and the migration of colon cancer cells. The inhibitory effects of Shi on (A) HCT116 and (B) SW620 cells using MTT assay after treatment with Shi for 24 and 48 h, respectively. Colony formation ability of (C) HCT116 and (D) SW620 cells treated with Shi at the indicated concentrations. (E) HCT116 and (F) SW620 cells were assessed using a wound-healing assay and the relative wound closure was calculated compared with the respective 0 h time point. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01vs. control DMSO group. Shi, shikonin.</p></caption>
<graphic xlink:href="ol-18-06-6117-g01.tif"/>
</fig>
<fig id="f3-ol-0-0-10980" position="float">
<label>Figure 3.</label>
<caption><p>Shi induces autophagy and reduces YAP expression in HCT116 and SW620 cells. The expression LC3-II and p62 were determined using western blot analysis in (A) HCT116 and (B) SW620 cells treated with an increasing concentration of Shi for 24 h and in (C) HCT116 and (D) SW620 cells treated with 10 &#x00B5;M Shi for 6, 12 and 24 h. YAP and p-YAP expression was determined using western blot analysis in (E) HCT116. YAP and p-YAP expression was determined using western blot analysis. (F) SW620 cells treated with an increasing concentration of Shi for 24 h and in (G) HCT116 and (H) SW620 cells treated with 10 &#x00B5;M Shi for 6, 12 and 24 h. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, compared with control. Shi, shikonin; p, phosphorylated; YAP, yes-associated protein.</p></caption>
<graphic xlink:href="ol-18-06-6117-g02.tif"/>
<graphic xlink:href="ol-18-06-6117-g03.tif"/>
</fig>
<fig id="f4-ol-0-0-10980" position="float">
<label>Figure 4.</label>
<caption><p>Shi reverses the influence of overexpressed YAP in HCT116 and SW620 cells. MTT assay was used to detect the effect of YAP overexpression in combination with 10 &#x00B5;M Shi on (A) HCT116 and (B) SW620 cell growth. YAP, LC3-II and p62 expression levels were determined using western blot analysis in (C) HCT116 and (D) SW620 cells transfected with YAP cDNA or treated with Shi. (E-H) Densitometry analysis of LC3-II, p62 and YAP. &#x002A;P&#x003C;0.05 compared with control. <sup>#</sup>P&#x003C;0.05, compared with YAP cDNA transfection. Shi, shikonin; YAP, yes-associated protein.</p></caption>
<graphic xlink:href="ol-18-06-6117-g04.tif"/>
</fig>
<fig id="f5-ol-0-0-10980" position="float">
<label>Figure 5.</label>
<caption><p>Knockdown of YAP increases sensitivity of HCT116 and SW620 cells to Shi. The effect of YAP downregulation in combination with 10 &#x00B5;M Shi on (A) HCT116 and (B) SW620 cell growth. YAP, LC3-II and p62 protein expression was measured using western blot analysis in (C) HCT116 and (D) SW620 cells transfected with YAP siRNA and treated with Shi. (E-H) Densitometry analysis of LC3-II, p62 and YAP. &#x002A;P&#x003C;0.05, compared with control. <sup>#</sup>P&#x003C;0.05, compared with YAP siRNA transfection. Shi, shikonin; YAP, yes-associated protein.</p></caption>
<graphic xlink:href="ol-18-06-6117-g05.tif"/>
</fig>
</floats-group>
</article>
